Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Thi6.5
Thiamidol – Forschung
Überwiegend Mechanismus / Beobachtung
9 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Thiamidol sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen randomisierten Studien, veröffentlicht 2018–2024 mit einer typischen Studiengröße von 48 Teilnehmenden.
Basierend auf 9 Studien · 5 RCTs · 2,128 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Skin tone & pigmentationmMASI reduction around 43% over 90 days in facial melasma, comparable to 4% hydroquinone; effect fades after stopping · 4-12 weeks
Überwiegend Mechanismus / Beobachtung8 Studien
Muscle strength & power
Zu wenige bewertete Studien2 Studien
Safety profile
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
7 Studien in den letzten 5 Jahren
20182024
1In vitroCited 159×2018
Einfach gesagt: Screening 50,000 compounds against recombinant HUMAN tyrosinase, thiamidol had an IC50 of 1.1 µmol/L, while hydroquinone and arbutin inhibited human tyrosinase only weakly, in the millimolar range.
Mann T, et al. · J Invest Dermatol (2018)
The discovery paper, and the reason this ingredient exists: most tyrosinase inhibitors were screened against MUSHROOM tyrosinase, which is why so many lack clinical effect.
Thiamidol inhibits human tyrosinase at IC50 1.1 µmol/L but mushroom tyrosinase only at 108 µmol/L — a hundredfold the other way round. The two enzymes need different molecules.
Hydroquinone and arbutin were weak on the human enzyme (millimolar IC50); kojic acid was weak too (IC50 > 500 µmol/L).
2RCTCited 40×n=50 · small study2021
Einfach gesagt: Over 90 days in 50 women with facial melasma, mMASI fell 43% (95% CI 35-50) with 0.2% thiamidol and 33% (95% CI 23-42) with 4% hydroquinone, with NO significant difference between the groups.
The comparison that matters: head to head against 4% hydroquinone, the prescription-strength benchmark.
⚠️ NOT a superiority result, and not a formal non-inferiority design either: mMASI fell 43% vs 33% and the paper states the improvement "did not differ" from 4% hydroquinone.
Evaluator-blinded, 50 women, 90 days; 86% were Fitzpatrick phototypes III-IV.
3Systematische ÜbersichtCited 14×n=1,853 · large study2022
Einfach gesagt: Across 47 studies and 1,853 subjects graded with a modified GRADE scale, thiamidol was among the agents with high-quality studies — while retinoids, hydroxy acids and broad-spectrum sunscreen were supported by the greatest number of them.
Chaowattanapanit S, et al. · J Dermatolog Treat (2022)
Independent context, not a thiamidol paper: 47 of 1,224 screened studies, 1,853 subjects, GRADE-assessed.
Thiamidol is listed among agents WITH high-quality studies, alongside retinoids, hydroxy acids, corticosteroids, niacinamide and plant-derived products.
⚠️ But retinoids, hydroxy acids and broad-spectrum sunscreen are the ones "supported by the greatest number of high-quality studies". Thiamidol is in the room, not leading it.
4RCTCited 20×n=48 · small study2021
Einfach gesagt: MASI improved significantly versus vehicle across 24 weeks, but at follow-up 13-20 weeks after treatment stopped, MASI was similar for thiamidol and vehicle.
Philipp-Dormston WG, et al. · J Dermatol (2021)
The study the abstract calls the FIRST 24-week randomized, double-blind, vehicle-controlled assessment of thiamidol in moderate-to-severe melasma, with a subsequent regression phase.
⚠️ The benefit did not persist. At follow-up 13-20 weeks after stopping, MASI was still below baseline but SIMILAR between thiamidol and vehicle.
⚠️ Skin lightness and quality of life improved versus baseline but showed NO significant difference between thiamidol and vehicle.
5RCTCited 9×n=40 · small study2023
Einfach gesagt: Replacing hydroquinone with isobutylamido-thiazolyl-resorcinol in a triple combination gave an mMASI change of -4.33 against -2.84 for Kligman’s trio, a mean difference of -1.49 (95% CI -3.52 to 0.54, p = 0.14).
Tests the ingredient inside the gold-standard regimen: ITR plus retinoic acid plus corticosteroid, against Kligman’s trio.
⚠️ NOT superior. The between-group difference was -1.49 with a 95% CI spanning zero (-3.52 to 0.54) and p = 0.14.
Quality of life did separate: MelasQoL -12.57 (p = 0.0006) for the new trio versus -6.66 (p = 0.0515) for Kligman’s.
6Systematische ÜbersichtCited 3×2024
Einfach gesagt: Across 14 clinical studies all reporting statistically significant improvement, the authors conclude that topical ITR can significantly reduce hyperpigmentation, however the evidence for its use is limited and further investigation is warranted.
Ashraf S, et al. · J Drugs Dermatol (2024)
The dedicated systematic review: 14 clinical studies across facial hyperpigmentation, melasma, post-inflammatory and UV-induced hyperpigmentation.
All 14 reported statistically significant improvement, across facial hyperpigmentation, melasma, PIH and UV-induced pigmentation.
⚠️ The review’s own verdict is hedged: "the evidence for its use is limited. Further investigation is warranted."
7Open-LabelCited 35×n=83 · small study2020
Einfach gesagt: An international multi-centre approach combining a double-blind, controlled, split-face study of four-times versus twice-daily thiamidol with an open-label, real-world study of a full Thiamidol-containing face care regimen.
Roggenkamp D, et al. · Int J Cosmet Sci (2020)
The dosing study: split-face, four-times daily versus twice daily, which is where the "2 to 4 times daily" guidance comes from.
Split-face design controls for the individual, which is a genuine strength for a pigmentation endpoint.
⚠️ Two studies in one paper: the split-face randomized half (n = 34) and an OPEN-LABEL observational real-world half (n = 83, chromametry on 30), which carries no control for expectation.
8RCTCited 16×n=30 · small study2021
Einfach gesagt: After three weeks of application in 30 participants, ITR-treated skin showed NO significant lightening on its own, but a significantly lower lightness index than control after UVB-induced pigmentation.
Wanitphakdeedecha R, et al. · J Cosmet Dermatol (2021)
The distinction this study draws is the useful one: ITR did NOT lighten untreated skin, but it blunted the darkening UVB caused.
⚠️ "Both experimental sides showed no significant difference in terms of skin lightening after ITR application" — it is not a general skin lightener.
A pilot: 30 healthy participants, randomized but SINGLE-blinded.
9RCTCited 5×n=24 · very small study2024
Einfach gesagt: Two weeks of twice-daily ITR before Q-switched Nd:YAG laser lowered the INCIDENCE of post-inflammatory hyperpigmentation at week 4 (20.83% vs 50%, p = 0.028), while RMI, mean L* and hyperpigmentation score showed no significant difference between treatments at any visit.
Wanitphakdeedecha R, et al. · J Cosmet Dermatol (2024)
A prevention use: pre-treating before laser to reduce post-inflammatory hyperpigmentation.
PIH incidence at week 4 was 20.83% with twice-daily ITR against 50% with no application (p = 0.028).
⚠️ Every CONTINUOUS measure was null — relative melanin index, mean luminance and hyperpigmentation score showed no significant difference at any visit. Only the binary incidence moved.